U.S. Senator Bill Cassidy, M.D. (R-LA), who chairs the Senate Health, Education, Labor, and Pensions Committee (HELP), is seeking details from Apexus regarding its revenue generation and business practices related to the 340B Drug Pricing Program. This request is part of Cassidy's ongoing investigation into the financial flows within the 340B Program to ensure it benefits American patients by reducing healthcare costs.
Dr. Cassidy said, "As I indicated in my report on the 340B Program last spring, a serious lack of transparency in the 340B Program prevents 340B discounts from translating to better access or lower costs for patients." He emphasized the need for information about how Apexus earns revenue and structures its commercial offerings concerning the program.
Since 2004, Apexus has held an exclusive contract with the Health Resources and Services Administration (HRSA) as the sole prime vendor for the 340B program. Its responsibilities include negotiating drug prices below statutory ceiling prices for covered entities and establishing distribution solutions to improve medication access. However, media reports revealed that Apexus generates significant revenue through fees on nearly every drug sold under the program and has expanded its business beyond its primary role.
Cassidy aims to enhance accountability and transparency within the 340B Program to ensure efficient operation that benefits patients without misaligned incentives. The full letter detailing this request can be accessed here.
